many newbies stucked in this stock back in few yrs ago. that why many ppl commenting bout this. last time the stock price shoot up due to newly built factory, new line of products plus top 30 stockholder including coldeyes. this stock price raised unusually high in 2 weeks, den today shot up 50%. i think its just matter of time drop back to lower point.
Solution Group Enters Into MoU With Cansino Biologics Inc. Aug 19 (Reuters) - Solution Group Bhd <SLEG.KL>::SOLUTION GROUP BHD- ENTERED INTO MOU WITH CANSINO BIOLOGICS INC..SOLUTION-MOU FOR COLLABORATION ON POTENTIAL COVID-19 VACCINE BY CANSINOBIO & BEIJING INSTITUTE OF BIOTECHNOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES.SOLUTION GROUP - SGB EXPECTS COLLABORATION WILL CONTRIBUTE POSITIVELY TO EARNINGS IN FUTURE.
The next top glove and sure better in the making. I'm pretty sure this stock will sky high. It will replace all attention in gloves market.china vaccine Clinical trial phase 3 will end in few months. And I'm pretty sure it will be cumpolsary to take this vaccine. Can u imagine in Malaysia itself we have 28millions people. Indonesia? ..etc. if 1 shot of vaccine is minimal rm200, it's will be madnesses profit for solution berhad!!! Just a 2 cents comment. Cheers.
The agreement was announced by Foreign Minister Retno Marsudi in a virtual press conference after a meeting with her Chinese counterpart Wang Yi.
Indonesian Foreign Minister Retno Marsudi (1st from left) and Erick Thohir, chief of the Committee for COVID-19 Mitigation and National Economic Recovery, pose in a photo with CEOs of Chinese drug-maker Sinovac Biotech Ltd. and Indonesian pharmaceutical company PT Bio Farma after witnessing the signing of memorandum of understanding between the two companies to develop COVID-19 vaccine in Sanya, China on Aug. 20, 2020. (Photo courtesy of Foreign Minister Retno Marsudi) (Kyodo) "A commitment was agreed on the supply of vaccine bulk up to 40 million doses from November 2020 to March 2021," Retno told reporters, saying the agreement was signed between Chinese drugmaker Sinovac Biotech Ltd. and Indonesia's PT Bio Farma.
Since last week, Indonesia has been conducting the final, phase 3 clinical testing for the COVID-19 vaccine candidate in the West Java provincial capital of Bandung.
The trial is taking place with the cooperation of Sinovac, which developed the vaccine candidate, with support from Bio Pharma and a team of Indonesian scientists and researchers.
Once clinical testing is completed, massive vaccine production will begin immediately and is expected to reach a level of 250 million doses annually, paving the way to offering immunity to the public.
During a visit to China, Retno and Erick Thohir, chief of the Committee for COVID-19 Mitigation and National Economic Recovery, also met with officials of other Chinese pharmaceutical companies, including Sinopharm Group Ltd. and CanSino Biologics Inc. to discuss possible cooperation in developing vaccines.
Retno said Indonesia is also in talks with other stakeholders outside China in efforts to get enough vaccine for the country's 270 million people amid tough competition for supplies.
As of Thursday noon, Indonesia reported 2,266 new confirmed cases of the coronavirus, bringing the total number of cases to 147,211 with 6,418 fatalities.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
stockraider
31,556 posts
Posted by stockraider > 2020-08-21 11:56 | Report Abuse
The key is cansino with solution on covid19 vaccine deal is a foregone conclusion mah....!!
The next question u should ask what sort of profit they can make with this deal leh ??
General Raider still finding out loh....!!